Urate Lowering Therapy in Patients With Subcutaneous Tophi
Author(s)
Morlock R1, Keenan RT2
1Probridge Solutions, White Lake, MI, USA, 2Arthrosi Therapeutics, San Diego, CA, USA
OBJECTIVES: To assess patient characteristics and treatment rates in patients with subcutaneous tophi.
METHODS: A 2017-2019 annual cross-sectional survey of US adults assessed health conditions, health-related quality of life (HRQoL), and health care resource utilization. Participants aged ≥18 years were recruited using a random stratified sampling framework to ensure demographic composition representative of the US population. Overall study participants who reported having gout completed a series of questions about current treatments, sUA laboratory assessments, disease severity, satisfaction with disease control and acute gout attacks (flares). Population level characteristics, treatment rates, sUA testing, and compliance measures are summarized using descriptive statistics.
RESULTS: A total of 103 (11.0%) of 933 participants with gout reported having visible tophi. Participant characteristics with tophi are presented in the Table. ULT use was reported in only 57 (55.3%) participants with subcutaneous tophi. Those subcutaneous tophi patients taking a ULT, 51 (89.5%) reported taking allopurinol, of those, 46 (90.2%) reported taking 300 mg or less per day. Those taking a ULT, 38 (66.7%) reported being compliant and always taking their medication as prescribed. Just over half, 53 (51.5%) reported having their sUA evaluated over the last 12 months with 21 (39.6%), 13 (24.5%), and 19 (34.5%) having their sUA tested 1, 2 or 3 times in the 12 month period, respectively. Of those with a sUA assessment, only 8 (28.6%) reported achieving a target sUA of <6 mg/dL.
CONCLUSIONS: A large percent of patients with subcutaneous tophi are not being treated with a ULT, and of those treated, nearly half do not achieve sUA <6 mg/dL or the recommended <5 mg/dL. New treatments and/or treatment strategies are needed to improve care for patients with subcutaneous tophi.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
EPH46
Topic
Epidemiology & Public Health, Study Approaches
Topic Subcategory
Surveys & Expert Panels
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), No Additional Disease & Conditions/Specialized Treatment Areas